BlackRock Maintains 6.0% Stake in Iovance Biotherapeutics
Ticker: IOVA · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, amendment, biotechnology
TL;DR
**BlackRock still owns 6.0% of IOVA, a bullish sign for stability.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership in Iovance Biotherapeutics, Inc. as of December 31, 2023. This filing indicates BlackRock's passive investment in the company, holding 15,483,398 shares of Common Stock, representing 6.0% of the outstanding shares. This matters to investors because BlackRock, a major institutional investor, maintains a significant stake, signaling continued confidence in Iovance Biotherapeutics, Inc. without seeking to influence management.
Why It Matters
This filing confirms BlackRock's continued significant, yet passive, investment in Iovance Biotherapeutics, Inc., which can be a positive signal for other investors regarding the stock's long-term prospects.
Risk Assessment
Risk Level: low — The filing indicates a passive investment by a large institutional holder, which generally reduces volatility and provides a degree of stability.
Analyst Insight
Investors should note BlackRock's continued significant, passive stake as a potential indicator of long-term institutional confidence in Iovance Biotherapeutics, Inc., but this filing alone doesn't suggest any immediate catalysts or changes in company direction.
Key Numbers
- 15,483,398 — Shares Owned (BlackRock's total beneficial ownership in Iovance Biotherapeutics, Inc.)
- 6.0% — Percentage Ownership (BlackRock's stake in Iovance Biotherapeutics, Inc. as of December 31, 2023)
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Iovance Biotherapeutics, Inc. (company) — the subject company in which BlackRock holds shares
- 15,483,398 shares (dollar_amount) — the total number of shares of Common Stock beneficially owned by BlackRock
- 6.0% (dollar_amount) — the percentage of Iovance Biotherapeutics, Inc.'s Common Stock owned by BlackRock
- December 31, 2023 (date) — the date of the event which required the filing of this statement
- January 26, 2024 (date) — the filing date of the SC 13G/A amendment
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in Iovance Biotherapeutics, Inc. throughout 2024. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
What is the purpose of this SC 13G/A filing by BlackRock Inc.?
This SC 13G/A is an amendment (Amendment No: 1) filed by BlackRock Inc. to update its beneficial ownership in Iovance Biotherapeutics, Inc. as of December 31, 2023, under Rule 13d-1(b) of the Securities Exchange Act of 1934.
How many shares of Iovance Biotherapeutics, Inc. Common Stock does BlackRock Inc. beneficially own?
As of December 31, 2023, BlackRock Inc. beneficially owns 15,483,398 shares of Common Stock of Iovance Biotherapeutics, Inc.
What percentage of Iovance Biotherapeutics, Inc.'s outstanding Common Stock does BlackRock Inc. own?
BlackRock Inc. owns 6.0% of the outstanding Common Stock of Iovance Biotherapeutics, Inc. as reported in the filing.
What is the significance of BlackRock filing under Rule 13d-1(b)?
Filing under Rule 13d-1(b) indicates that BlackRock Inc. is an institutional investor (like a registered investment adviser or bank) that acquired the shares in the ordinary course of business and not with the purpose or effect of changing or influencing the control of Iovance Biotherapeutics, Inc. This signifies a passive investment.
When was the event date that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding IOVANCE BIOTHERAPEUTICS, INC. (IOVA).